Amarin Corp Plcuk (AMRN) Assets Average (2011 - 2026)
Amarin Corp Plcuk (AMRN) reported Assets Average of $658.3 million for Q1 2026, down 1.83% year-over-year from $670.5 million in Q1 2025, and down 1.06% quarter-over-quarter from $665.3 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Assets Average (2011 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 16 years of Assets Average data on file, last reported at $658.3 million in Q1 2026.
- Assets Average for Q1 2026 came in at $658.3 million, down 1.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $658.3 million (down 1.83% YoY), and the FY2025 annual result was $678.1 million, down 10.61% from the prior year.
- Assets Average eased to $658.3 million in Q1 2026 per AMRN's latest filing, from $665.3 million in the prior quarter.
- Over five years, Assets Average peaked at $1.0 billion in Q1 2022 and troughed at $658.3 million in Q1 2026.
- A 5-year average of $804.2 million and a median of $810.8 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average advanced 4.37% in 2022, then retreated 17.31% in 2025.
- A 5-year view of Assets Average shows it stood at $897.2 million in 2022, then fell by 6.9% to $835.4 million in 2023, then dropped by 14.05% to $718.0 million in 2024, then fell by 7.34% to $665.3 million in 2025, then decreased by 1.06% to $658.3 million in 2026.
- Business Quant data shows AMRN's Assets Average at $658.3 million in Q1 2026, $665.3 million in Q4 2025, and $665.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 83.03 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 114.53 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 200.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 135.21 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 88.26 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 658.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 658.27 Mn |
| Dec 31, 2025 | 665.29 Mn |
| Sep 30, 2025 | 664.97 Mn |
| Jun 30, 2025 | 662.91 Mn |
| Mar 31, 2025 | 670.52 Mn |
| Dec 31, 2024 | 717.98 Mn |
| Sep 30, 2024 | 775.26 Mn |
| Jun 30, 2024 | 794.96 Mn |
| Mar 31, 2024 | 810.85 Mn |
| Dec 31, 2023 | 835.36 Mn |
| Sep 30, 2023 | 849.52 Mn |
| Jun 30, 2023 | 860.10 Mn |
| Mar 31, 2023 | 873.18 Mn |
| Dec 31, 2022 | 897.24 Mn |
| Sep 30, 2022 | 940.77 Mn |
| Jun 30, 2022 | 973.47 Mn |
| Mar 31, 2022 | 1.02 Bn |
| Dec 31, 2021 | 1.05 Bn |
| Sep 30, 2021 | 1.04 Bn |
| Jun 30, 2021 | 1.02 Bn |